Cibc World Markets Corp Purchases Shares of 12,563 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Cibc World Markets Corp acquired a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) in the 4th quarter, HoldingsChannel reports. The firm acquired 12,563 shares of the biotechnology company’s stock, valued at approximately $113,000.

Other hedge funds also recently modified their holdings of the company. SBI Securities Co. Ltd. acquired a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $25,000. Blue Trust Inc. raised its position in Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 6,174 shares during the last quarter. FMR LLC boosted its stake in Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 3,919 shares in the last quarter. Union Bancaire Privee UBP SA bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $108,000. Finally, Bailard Inc. acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at $128,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

Shares of Aurinia Pharmaceuticals stock opened at $8.46 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The firm has a 50 day simple moving average of $8.09 and a 200 day simple moving average of $8.02. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.67. The firm has a market cap of $1.16 billion, a P/E ratio of -56.40 and a beta of 1.26.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the sale, the chief executive officer now owns 1,953,892 shares in the company, valued at $15,631,136. The trade was a 9.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Greg Keenan sold 8,305 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the sale, the insider now directly owns 153,484 shares of the company’s stock, valued at approximately $1,263,173.32. This trade represents a 5.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 343,898 shares of company stock worth $2,753,094. Insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.